A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD)
Phase 3 randomized trial (EMBARK) of one dose of delandistrogene moxeparvovec, an AAVrh74 micro-dystrophin gene therapy, in 125 ambulatory boys aged 4 to under 8 with Duchenne muscular dystrophy. The week-52 primary endpoint, NSAA score change, was not met (2.57 vs 1.92 points).
| Status | Completed |
|---|---|
| Phase | Phase 3 |
| Primary Endpoint Result | Not Met |
| Enrollment | 126 |
| Start Date | 2021-10-27 |
| Primary Completion Date | 2023-10-04 |
Results Summary
The dose was 1.33 x 10^14 vector genomes per kg. At week 52 (Part 1, data cut 13 September 2023), the NSAA total score rose by a least squares mean of 2.57 points with delandistrogene moxeparvovec (n=63) and 1.92 with placebo (n=61 analysed); the difference was 0.65 (95% CI -0.45 to 1.74; P=0.2441), so the primary endpoint was not met. Time to rise from the floor (-0.64 s) and 10-meter walk/run (-0.42 s) favored treatment, but the authors state no statistical significance can be claimed. Week-12 micro-dystrophin by western blot was 34.29% of normal in 17 treated patients versus 0.00% in 14 on placebo. Serious adverse events occurred in 14 of 63 treated and 5 of 62 on placebo; 7 treated patients (11.1%) had 10 treatment-related serious events, mainly acute liver injury, and all resolved. There were no deaths. At 2 years, treated patients (n=63) differed from a propensity-weighted external control (n=143) on NSAA change (+2.63 vs -0.25 points, nominal P=0.0001).
Design Implications
Expression of micro-dystrophin at about one third of normal did not produce a significant NSAA gain at one year in boys aged 4 to 7 who were still gaining skills on corticosteroids. Trials of dystrophin-restoring therapy at this age need endpoints and follow-up that detect early divergence: timed function tests and wearable stride velocity moved in favor of treatment where NSAA did not. A 1-year placebo arm with crossover leaves long-term claims resting on an external control, so a controlled durability readout needs a longer parallel control or prospectively matched natural history. Systemic AAVrh74 at 1.33 x 10^14 vg/kg caused transient liver enzyme elevations in 41% of treated boys within 90 days despite added corticosteroids, so liver monitoring is required. No complement-mediated events or thrombotic microangiopathy occurred, consistent with a non-human-primate capsid and screening out patients with elevated anti-AAVrh74 antibodies.
Rationale
Duchenne muscular dystrophy is caused by loss-of-function variants in the DMD gene, so muscle fibers lack dystrophin and degenerate. The DMD gene is too large for an AAV vector, so delandistrogene moxeparvovec (SRP-9001) delivers a shortened micro-dystrophin transgene that keeps the key functional domains of dystrophin. The transgene is packaged in an AAVrh74 capsid, chosen for efficient muscle transduction and low pre-existing immunity, and is driven by the muscle-specific MHCK7 promoter with a cardiac enhancer. One intravenous dose was expected to express micro-dystrophin in skeletal and heart muscle and slow the loss of motor function.
Limitations
One randomized comparison in 125 treated boys on stable corticosteroids, placebo-controlled for only 52 weeks. The primary endpoint was not met, so secondary results are descriptive and not adjusted for multiplicity. Week-104 efficacy compares 63 treated patients with a propensity-weighted external control whose corticosteroid dosing is unknown. Micro-dystrophin was measured in a biopsy subset (n=31 at week 12). Sponsor-run trial; authors include sponsor employees.
Registry record
The study will evaluate the safety and efficacy of gene transfer therapy in boys with DMD. It is a randomized, double-blind, placebo-controlled study. The participants who are randomized to the placebo arm will have an opportunity for treatment with gene transfer therapy at the beginning of the second year.
| Primary Outcomes | Part 1: Change From Baseline in North Star Ambulatory Assessment (NSAA) Total Score at Week 52 |
|---|---|
| Keywords | Muscular Dystrophies, Duchenne Muscular Dystrophy, DMD, North Star Ambulatory Assessment (NSAA), Ambulatory, Pediatric, Gene-Delivery |
| Maximum Age | 7 Years |
| Intervention Names | delandistrogene moxeparvovec, SRP-9001, delandistrogene moxeparvovec-rokl, ELEVIDYS, placebo |
| Primary Purpose | Treatment |
| Has Results | Yes |
| Countries | United States, Belgium, Germany, Hong Kong, Italy, Japan, Spain, Taiwan, United Kingdom |
| Intervention Types | genetic |
| Study Type | Interventional |
| Healthy Volunteers | No |
| Lead Sponsor Class | Industry |
| Eligibility Sex | Male |
| Registry Last Updated | 2025-07-08 |
| Results First Posted Date | 2024-12-10 |
| Minimum Age | 4 Years |
| Modalities | gene_therapy |
| Allocation | Randomized |
| Masking | Quadruple |
| Acronym | EMBARK |
| Enrollment Type | Actual |
| Intervention Model | Parallel |
| Condition Terms | Duchenne Muscular Dystrophy, Muscular Dystrophy, Duchenne, Muscular Dystrophies |
| Completion Date | 2024-10-25 |
Official Title
A Phase 3 Multinational, Randomized, Double-Blind, Placebo-Controlled Systemic Gene Delivery Study to Evaluate the Safety and Efficacy of SRP-9001 in Subjects With Duchenne Muscular Dystrophy (EMBARK)
Eligibility Criteria
Inclusion Criteria:
- Is ambulatory and from 4 to under 8 years of age at time of randomization.
- Definitive diagnosis of DMD based on documented clinical findings and prior genetic testing.
- Ability to cooperate with motor assessment testing.
- Stable daily dose of oral corticosteroids for at least 12 weeks prior to Screening, and the dose is expected to remain constant throughout the study (except for modifications to accommodate changes in weight).
- rAAVrh74 antibody titers are not elevated as per protocol-specified requirements.
- A pathogenic frameshift mutation or premature stop codon contained between exons 18 and 79 (inclusive), with the exception of mutation fully contained within exon 45.
Exclusion Criteria:
- Exposure to gene therapy, investigational medication, or any treatment designed to increase dystrophin expression within protocol specified time limits.
- Abnormality in protocol-specified diagnostic evaluations or laboratory tests.
- Presence of any other clinically significant illness, medical condition, or requirement for chronic drug treatment that in the opinion of the Investigator creates unnecessary risk for gene transfer.
Other inclusion or exclusion criteria could apply.
Identifiers & revision
clinicaltrials NCT05096221euclinicaltrials 2019-003374-91
